N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
New Approaches to Neuroblastoma Therapy Consortium
Institut du Cancer de Montpellier - Val d'Aurelle
National Cancer Institute (NCI)
IFOM ETS - The AIRC Institute of Molecular Oncology
Eli Lilly and Company
Grupo Español de Investigación en Neurooncología
Istituto Oncologico Veneto IRCCS
Mayo Clinic
Stanford University
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
National Cancer Institute (NCI)
Stanford University
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
University of Iowa
Oblato, Inc.
Emory University
Mayo Clinic
European Organisation for Research and Treatment of Cancer - EORTC
Jiangsu HengRui Medicine Co., Ltd.
Washington University School of Medicine
Case Comprehensive Cancer Center
Bristol-Myers Squibb
BioMimetix JV, LLC
Columbia University
MediciNova
Thomas Jefferson University
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Washington University School of Medicine
Massachusetts General Hospital
Candel Therapeutics, Inc.
International Extranodal Lymphoma Study Group (IELSG)
Children's Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Centre Hospitalier Universitaire de Besancon
University of Iowa
BeiGene
Gustave Roussy, Cancer Campus, Grand Paris
Hackensack Meridian Health
Children's Oncology Group
Jonsson Comprehensive Cancer Center
Impact Therapeutics, Inc.
Radiation Therapy Oncology Group
Northwell Health
M.D. Anderson Cancer Center